The exorbitant cost of prescription drugs continues to be one of the biggest drains on the healthcare system. The Food and Drug Administration in June took steps to increase competition by posting a list of branded drugs that are not protected by patent and are not facing looming generic drug rivals. The agency will fast-track its review of generic drug applications. Download the PDF.
Data Points: Growth in generics doing little to curb drug prices
Data Points for July 10, 2017
Letter
to the
Editor
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.
Sponsored Content